| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.081 | 0.02 |
| mRNA | AC55649 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.02 |
| mRNA | UNC0638 | GDSC1000 | pan-cancer | AAC | 0.074 | 0.02 |
| mRNA | UNC0638 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.02 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.091 | 0.02 |
| mRNA | thapsigargin | gCSI | pan-cancer | AAC | -0.14 | 0.02 |
| mRNA | BRD-K04800985 | CTRPv2 | pan-cancer | AAC | 0.091 | 0.02 |